Clinic
Namita Mohideen MD INC
Namita Mohideen MD INC was paid $3.39M by Medicaid between May 2018 and Nov 2024, across 90 billing codes. Its largest line is 96156, — 25% of everything it billed.
33Billing provider infoNAMITA MOHIDEEN MD INC
FONTANA, CA 92336
FONTANA, CA 92336
33aNPI1649546144assigned 03/29/2012
33bProvider typePrimary Care Clinic/Center
28Total paid$3.39M
24GClaims157,849
24DCodes billed90
24AFirst – last monthMay 2018 – Nov 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in California
Rank by total paid#27 of 422
Median peer was paid$25K
This provider vs. median138×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 232 | $5K | |
| 2019 | 8,715 | $218K | |
| 2020 | 12,111 | $205K | |
| 2021 | 16,374 | $322K | |
| 2022 | 24,184 | $602K | |
| 2023 | 37,462 | $887K | |
| 2024incomplete | 58,771 | $1.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96156 | 25% | 10,774 | 10,743 | $860K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 13,495 | 12,281 | $519K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 15,043 | 13,984 | $358K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.5% | 4,051 | 3,973 | $187K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.1% | 5,332 | 5,307 | $172K |
| 92552 | 4.3% | 9,954 | 9,923 | $146K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.5% | 3,391 | 3,376 | $119K |
| G9920 | Screening performed and negative | 3.4% | 12,819 | 12,730 | $114K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.1% | 1,706 | 1,705 | $72K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 2.1% | 7,254 | 7,139 | $70K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 1.7% | 3,940 | 3,937 | $59K |
| 99381 | 1.6% | 748 | 748 | $55K |
78 more codes
| 99188 | 1.5% | 3,329 | $50K | |
| 99383 | 1.4% | 767 | $46K | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 1.2% | 2,124 | $40K |
| 90697 | 1.2% | 1,741 | $40K | |
| 96127 | <1% | 6,869 | $34K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 743 | $33K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 461 | $30K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,556 | $30K |
| 90686 | <1% | 3,713 | $28K | |
| 99382 | <1% | 394 | $25K | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 953 | $25K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 324 | $24K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 158 | $18K |
| 99000 | <1% | 5,276 | $17K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,650 | $16K |
| 90671 | <1% | 1,798 | $16K | |
| 83655 | <1% | 1,537 | $13K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 122 | $12K |
| 99205 | Prolong outpt/office vis | <1% | 141 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 405 | $12K |
| 90633 | <1% | 1,474 | $11K | |
| 90670 | <1% | 1,696 | $11K | |
| 90651 | <1% | 1,235 | $9K | |
| 90680 | <1% | 1,262 | $9K | |
| 99384 | <1% | 135 | $9K | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 3,466 | $7K |
| 85018 | <1% | 3,745 | $7K | |
| 90698 | <1% | 1,182 | $6K | |
| 0071A | <1% | 142 | $6K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 1,201 | $5K |
| 0072A | <1% | 123 | $5K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 45 | $5K |
| 90656 | <1% | 558 | $4K | |
| 90716 | <1% | 546 | $4K | |
| 90707 | <1% | 543 | $4K | |
| 99385 | <1% | 31 | $4K | |
| 90710 | <1% | 471 | $4K | |
| 90619 | <1% | 422 | $4K | |
| 90696 | <1% | 451 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 197 | $2K |
| 0002A | <1% | 53 | $2K | |
| 0001A | <1% | 43 | $2K | |
| 90744 | <1% | 407 | $2K | |
| 90681 | <1% | 192 | $2K | |
| 98960 | <1% | 69 | $1K | |
| 99173 | <1% | 361 | $1K | |
| 90715 | <1% | 172 | $1K | |
| 90480 | <1% | 30 | $1K | |
| 90620 | <1% | 168 | $1K | |
| 94760 | <1% | 203 | $1K | |
| 81002 | <1% | 471 | $798.75 | |
| 92551 | <1% | 87 | $738.34 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 83 | $512.08 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 268 | $465.82 |
| 90734 | <1% | 116 | $404.73 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $278.40 |
| 91319 | <1% | 13 | $263.34 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25 | $202.80 |
| 90700 | <1% | 12 | $98.01 | |
| 86580 | <1% | 27 | $80.25 | |
| 87081 | <1% | 14 | $73.06 | |
| 96160 | <1% | 868 | $66.02 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $57.46 |
| 4004F | <1% | 5,215 | $33.75 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 180 | $28.78 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 214 | $18.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 72 | $17.52 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $1.89 |
| 3074F | 0% | 1,304 | $0.00 | |
| 96161 | 0% | 3,585 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 91 | $0.00 |
| 3079F | 0% | 509 | $0.00 | |
| 3080F | 0% | 42 | $0.00 | |
| 3075F | 0% | 156 | $0.00 | |
| 3044F | 0% | 104 | $0.00 | |
| 3078F | 0% | 1,021 | $0.00 | |
| 3077F | 0% | 104 | $0.00 | |
| 90461 | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOHIDEEN, NAMITA (DOCTOR)
| Provider | Location | Paid |
|---|---|---|
| Victorville Pediatrics | Victorville, CA | $562K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.